@article{a468c949942d42d9a29a89807ed149a2,
title = "Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma",
author = "Bachar Samra and Alotaibi, {Ahmad S.} and Short, {Nicholas J.} and Khoury, {Joseph D.} and Farhad Ravandi and Rebecca Garris and Nitin Jain and Marina Konopleva and Hagop Kantarjian and Elias Jabbour",
note = "Funding Information: E. Jabbour: Research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. F. Ravandi: Honoraria/member advisory boards with BMS, Novartis, AbbVie and Amgen. M. Konopleva: Consulting/honoraria from AbbVie, Genentech, F. Hoffman La‐Roche, Stemline Therapeutics, Amgen, Forty‐Seven, Kisoji; research funding/clinical trials support: AbbVie, Genentech, F. Hoffman La‐Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca, Forty‐Seven; stock options/royalties: Reata Pharmaceutical. H. Kantarjian: Grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi‐Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. N.J. Short has served as consultant for Takeda Oncology and AstraZeneca, reports receiving commercial research grants from Takeda Oncology and Astellas Pharma Inc., and has received speakers{\textquoteright} bureau honoraria from Amgen. ",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/ajh.25896",
language = "English (US)",
volume = "95",
pages = "E245--E247",
journal = "American journal of hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",
}